Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Androgenetic Alopecia Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

NCT01451151
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
2
States / cities
Los Angeles, California • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Jul 22, 2026, 11:12 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

NCT06482541
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling
Combination Product
Lead sponsor
Levit Dermatology
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jul 22, 2026, 11:12 PM EDT
Withdrawn Phase 4 Interventional

Hydraderm for Androgenic Alopecia

NCT05426629
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Venus Glow
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 22, 2026, 11:12 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

NCT02676310
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 22, 2026, 11:12 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

NCT06926023
View directory record Official record
Conditions
Female Pattern Baldness
Interventions
1550nm non-ablative fractional laser, 1927 thulium fractional laser
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

NCT03495817
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

NCT01451021
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 22, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

Computer-Assisted Hair Restoration Study Using ARTAS System

NCT05938569
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Hair restoration
Device
Lead sponsor
Venus Concept
Industry
Eligibility
20 Years to 70 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Los Altos, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia

NCT02460497
View directory record Official record
Conditions
Female Pattern Hair Loss, Androgenic Alopecia
Interventions
Treatment: Minoxidil 2% / Botanical Hair Solution for Women
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenetic Alopecia in Females, 9 Beam

NCT00981461
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
Interventions
HairMax LaserComb, Control Device
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Miami, Florida • Palm Beach, Florida • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

NCT06112782
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Keravive by Hydrafacial Treatments
Device
Lead sponsor
Beauty Health
Industry
Eligibility
30 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT04913519
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Jul 22, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of VDPHL01 in Males With AGA

NCT06972264
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

NCT01325337
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Jul 22, 2026, 11:12 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

NCT02483195
View directory record Official record
Conditions
Female Androgenetic Alopecia
Interventions
5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Jul 22, 2026, 11:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Androgenetic Alopecia in Fabry Disease

NCT01295008
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

NCT06927960
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
AH-001 or placebo
Drug
Lead sponsor
AnHorn Medicines Co. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 22, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

NCT07107841
View directory record Official record
Conditions
Androgenic Alopecia, Alopecia, Baldness
Interventions
Autologous Hair Follicle-Derived Secretome, Placebo Control
Other
Lead sponsor
Acorn Biolabs Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

NCT02781311
View directory record Official record
Conditions
Alopecia
Interventions
Setipiprant, Placebo, Finasteride
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Jul 22, 2026, 11:12 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of VDPHL01 in Males and Females With AGA

NCT06527365
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
San Diego, California • New Albany, Indiana • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 11:12 PM EDT
Completed Phase 1Phase 2 Interventional

Activated PRP for Treatment of Androgenetic Alopecia

NCT05348343
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Autologous platelet-rich plasma
Biological
Lead sponsor
Santiste Medical Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 22, 2026, 11:12 PM EDT
Not yet recruiting Not applicable Interventional

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

NCT07637071
View directory record Official record
Conditions
Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
Interventions
Xtressé Hair Growth Gummies
Other
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 11:12 PM EDT